EP239: Beyond Mold: The Continent of the Cell Danger Response - Part 1 - Andrew Heyman, MD, MHSA
In a Nutshell
Dr. Andrew Heyman argues that CIRS and related chronic illnesses are subsets of a broader mitochondrial disorder called the Cell Danger Response (CDR), where mitochondria shift from energy production to survival mode under accumulated stressors. Recovery requires a three-phase approach: CDR1 extinguishes the inflammatory "house on fire" by removing triggers and reducing load; CDR2 rebuilds metabolism and mitochondrial function; CDR3 restores safety signals through VIP, vagal recalibration, and emotional trauma work. The process typically takes two years because each phase is biologically gated, and patients must address total load rather than single triggers.
These notes were generated by AI and may contain inaccuracies.
The Better Health Guide podcast explores complex chronic conditions and strategies for building resilience, improving vitality, and achieving better health. Content is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing discussed should be considered medical advice. Listeners are advised to discuss health-related decisions with their own personal medical authority.
Episode 239 features Dr. Andrew Heyman, an internationally recognized expert in integrative and metabolic medicine. He serves as fellowship director of integrative medicine at George Washington University, overseeing graduate education and multiple degree programs. He created the first master's degree in integrative medicine in the United States within a major academic center and developed graduate curricula in nutrition, metabolic medicine and performance, men's health, biotoxin exposure and neurodegeneration, and administrative health services in wellness settings.
Dr. Heyman has held board certifications in family medicine, integrative medicine, and anti-aging and regenerative medicine. He served as director of academic affairs for the American Academy of Anti-Aging Medicine for a decade, overseeing all educational programs globally. Since 2014, his clinical and research focus has been on biotoxin illnesses and exposure to water-damaged buildings. He has published nearly two dozen peer-reviewed papers and edited the first medical textbook on the topic.
Dr. Heyman began his health journey early, training at age 17 in traditional Chinese medicine and Japanese Zen Shiatsu. He was introduced to Shiatsu during a Tai Chi course and felt an immediate connection to this approach and worldview. Despite his parents' concerns about his pursuit of Chinese medicine, he pursued certification and graduated college.
Trained by Zen and Tibetan Buddhist monks, as well as experts from Thailand, Vietnam, Japan, and China, this training changed how he saw himself and the world. It inspired both mindfulness and a commitment to health optimization. After college, he trained seriously for triathlons, following various diets including vegan and macrobiotic approaches.
During his fourth year of medical school at University of Michigan, Dr. Heyman completed an elective at an integrative clinic in rural Virginia. While training for an Ironman, he discovered an embedded tick on the back of his left knee after a six-mile recovery run. He removed it without concern, having no education about Lyme disease in medical school, residency, or post-residency training.
A few months later, he developed shortness of breath, excessive sweating, and anxiety. He began sweating through clothing and used towels or tissue paper under his arms. He even obtained Botox injections under his arms. His fitness declined rapidly, preventing him from completing the Ironman. He attributed symptoms to residency stress initially.
Ten years later, while working at the same Virginia integrative clinic, he recognized that self-described Lyme patients had identical symptoms to his own. A neurologist had previously noted he had Bell's palsy during a rotation, but he did not connect this to his declining health at the time.
The discussion focuses on approaching recovery from complex chronic illness through the cell danger response (CDR) lens. Dr. Heyman notes that the Shoemaker CIRS (Chronic Inflammatory Response Syndrome) treatment model, while brilliant, is now 20 years old. The 12-stage process ending with VIP (vasoactive intestinal peptide) has not been updated despite new insights.
Dr. Heyman was involved from the beginning of NeuroQuant research, the development of GENIE testing, papers on Actinomyces, endotoxins, and beta-glucans, and more recent work on Parkinson's and the triple positive concept. He reached what he describes as an intellectual limit with the CIRS framework.
The science underlying illness revealed that CIRS was essentially a mitochondrial disorder. The relevant genes showing pattern abnormality were mitochondrial in origin. This led Dr. Heyman to explore published research on mitochondrial acquired illnesses.
Dr. Robert Naviaux's work at UC San Diego provided the key organizing principle. Using sophisticated mitochondrial metabolomics, Naviaux demonstrated a predictable coordinated mitochondrial response to cellular threats. This revealed that the mitochondria, not the nucleus, represent the center of the cell designed to keep people alive and protect health and vitality.
Dr. Heyman describes CIRS as a country within the larger continent of cell danger response. The CDR model validates the CIRS framework: innate immune inflammation to a trigger, transition to hypometabolism and aerobic glycolysis, and the need for a safe pathway home with signals like VIP. However, CDR encompasses a broader landscape beyond these limited ideas.
The mitochondria shift from energy plants to battleships when faced with threats, moving into survival mode. This protective response triggers the integrated stress response of the mitochondria, which then signals the cell membrane to activate CDR1.
The CDR model applies to ME/CFS, long COVID, fibromyalgia, multiple sclerosis, Parkinson's, ALS, cancer, autism, PANS/PANDAS, and other conditions. Dr. Heyman notes that experts in mold, Lyme, mast cell activation, long COVID, and ME/CFS are essentially describing the same process from different entry points.
All conditions involve mitochondria being loaded with threat after threat until they shift into battleship mode. The specific label depends on the primary instigating trigger—Lyme, stress, mold, or other factors—but patients end up in the same physiological state.
Dr. Heyman emphasizes that entry into CDR1 results from loading exposures and loading triggers rather than single exposures. People vary in their resiliency and reserves. Some can absorb tremendous amounts of exposures, stress, and toxins while remaining healthy due to intact resiliency systems. Others reach a limit where the load overwhelms resiliency, triggering the mitochondrial shift.
The bucket analogy describes symptoms as the overflowing of the bucket. Creating margin in the bucket reduces or eliminates symptoms. Approaches include opening more drains through detoxification and drainage support, turning off the faucet by removing or reducing triggers, or increasing bucket size by addressing genetic predispositions, nervous system wiring, and sympathetic dominance.
CDR1 represents the active exposure phase where the house is on fire. Something triggers innate inflammation. In CIRS terminology, this involves biotoxins—organisms or fragments of organisms including mold, Actinomyces, endotoxins, and beta-glucans. Naviaux's research shows that heavy metals, chemicals, emotional stress, and physical stressors can also trigger this mechanism.
The mitochondria wait for the right signals at the right time to transition from CDR1 to CDR2 to CDR3. Treatment requires simultaneously reducing the load while building resiliency and sending safety signals.
The mitochondria are attuned to all sorts of potential threats including heavy metals, chemicals, emotional stress, physical trauma, traumatic brain injury, and EMFs. The approach focuses first on CDR1 to identify what's in that bucket and what can be drained, which includes both turning off inflammation and draining toxins resident in tissues and cell membranes. The sequence moves from reducing inflammation first, then detox, then microbial recovery especially with the gut. This is an exposure-based model that also addresses resiliency which lives mostly in CDR3 with safety signals including VIP.
After reducing exposure, turning off inflammation, passing visual testing, draining chemicals and metals, addressing microbes, sealing linings and barriers, and improving the microbiome, patients transition to CDR2 because the alarm is off and the house needs rebuilding. This involves metabolism at large including nutrients, hormones, and diet, but the biggest gap has been how to measure mitochondria directly. The closest test available is Genie, but it's an adjacent test measuring signals sent from DNA rather than what mitochondria are doing today.
Without direct mitochondrial measurement, it's difficult to know where patients are at in their recovery. Many patients who check all boxes for proper VIP protocol still have overlooked mitochondrial problems when tested. The conditions are trauma-based illnesses where patients are both hyperreactive and exhausted, needing safety and sanctuary signals.
The scope of trauma extends beyond capital T trauma to include all ways danger signals are sent to the mind and body. Navio's work established that these signals also live in the soma and mitochondria, with the same signals of danger and threat arriving at the cell membrane and transitioning down to mitochondria. There's a coordinated cellular response that mirrors and maps emotional responses. Just as adverse childhood events can leave people emotionally stuck and reliving trauma, cells can have exposures that turn on cell danger response even after the exposure is removed, leaving patients stuck in cellular patterns.
Molecular scarring is the notion that people remain stuck in patterns even after exposures are removed. The model remains symmetrical whether the event is emotional, physical, or something in between. This results in a broken nervous system, broken immune system, mitochondria that won't transition, and a psyche so injured that therapy can't reach emotional balance.
The term cellular rumination describes the subconscious replaying of trauma at the cell level. These defense mechanisms are designed to preserve life by maintaining high alert status, but result in hyperreactivity to smells, sounds, emotional stress, food, and normal life experiences. This characterizes the mast cell community and hypersensitive community within CIRS, where mitochondria react to everything due to lost reserve.
Standard workups were never built to detect a body stuck in chronic alarm state from environmental exposure. The visual test is described as searching a dark room with a flashlight pointed at the wrong wall when looking for mold illness. Tests from the CIRS toolbox that remain important include VCS, HLA, TGF beta 1, C4A, MMP9, MSH, Neuroquant, and Genie.
In CDR1 where the house is on fire, the most helpful marker is the visual test as a direct measure of central neurologic inflammation. The discipline of moving people through improving their visual test first before addressing diet, detox, hormones, or peptides is essential because none of those approaches work well with central buried inflammation. A new modern visual test has been developed with improved calibration for grayscale and pixel size.
MMP9 is the next most direct inflammatory marker as a direct measure of tissue level inflammation. C4A and C3A are valuable but getting proper testing is challenging since Colorado is the only place that runs it correctly. LabCorp adds preservative making results unreliable. Standard inflammatory markers like IL6, CRP, and neutrophil to lymphocyte ratio provide additional tools.
Once patients pass the visual test, the approach shifts to a Neil Nathan model where urine mycotoxin testing may be done to identify residual internal exposure. This is where detox agents like acetylcysteine, glutathione, charcoal, chlorella, and clay become relevant. The CIRS world considers urine mycotoxin testing too blunt an instrument, but blending both approaches allows full clean out using both visual test transition and mycotoxin testing when appropriate.
After visual test transition, chemical testing and heavy metal testing can be pursued depending on patient history. Background in chelation and heavy metal work makes this assessment natural. The sequence moves from inflammation assessment using visual test and other markers, then into pathogens and detox, then into the gut for CDR1.
An IRB approved research study on Neuroquant with Dr. Ross examines 240 brain centers compared to the original 11 centers. Dr. Ross is triple board certified in neurology, psychology, and traumatic brain injury with at least 20 publications on structural MRI with related exposures. The patterns of injury show that mold exposure most closely maps to traumatic brain injury, particularly in the degree of interstitial edema or inflammation and swelling.
TBI patterns show areas that both swell and shrink or atrophy, which is unique since most brain diagnoses show only atrophy. Mold exposure shows on average more swelling and less shrinking than TBI patterns. The algorithms currently being used are outdated, and new models are being built for better interpretation rather than using old blunt instrument approaches.
Genie measures the transcriptome level of omics, specifically RNA signals off mitochondrial DNA. Genetics measures gene structure inherited from parents, while genomics measures gene function and signals that come off DNA. The omics layers progress from genome (DNA) to transcriptome (RNA) to proteome (proteins) to metabolome (small molecules). Navio's work measures the metabolome as the end expression of mitochondrial function.
Up to 40% of RNA signals appear in the metabolome with huge variability between DNA signals and metabolic outcomes due to regulation at every layer of the omics model. Genie is helpful diagnostically to identify exposure patterns, inflammation, hypometabolism, proliferative physiology, and CDR elements. However, using it as a predictive tool for current or future illness is problematic due to signal extinction, transience, and lack of required genome data, clinical context, and sample size.
Section 3 of Genie (apoptosis category with caspases) can indicate beta-glucans or fungal elements. Section 9 (MAP kinases) and Section 10 (toll-like receptors) have different utility. MAP kinases are stress signaling pathways not specific to mold or actinomyces exposure, representing general cellular stress rather than specific causation. Section 10 toll-like receptors are induced by lipopolysaccharides and endotoxins, making this finding more reliable for indicating endotoxin presence.
The CIRS model fails to account for endogenous endotoxin production from gram-negative bacteria in the gut microbiome. Genie may be picking up internal endotoxins in addition to external ones. MTHFR and SNPs have not been found to play a big role in this illness or recovery, and the persona of brokenness or not fixable that some patients adopt can be counterproductive.
Epigenetic factors influence overall genetic expression more broadly than MTHFR alone. The focus should shift from SNIPS as potential risk factors to evaluating actual function rather than potential.
HLA 4353 is commonly considered more difficult, though terminology should avoid framing it as a negative safety signal. One individual's experience with HLA 4353 showed the journey to recovery was challenging but not deterministic based on this genetic marker. HLA status does not predict vulnerability to developing conditions upon trigger exposure or potential for recovery. HLA messaging can function as the opposite of a safety signal depending on how it's communicated. Total load matters more than HLA status.
University genetic counseling centers indicate very few genes are deterministic for health outcomes. Only under very specific circumstances do certain inherited genes fundamentally alter health trajectories through critical pathway disruption. Inborn errors of genetic mutations and SNIPS have been greatly overstated, particularly in functional medicine where MTHFR became the central focus for chronic fatigue syndrome, chronic infections, poor detoxification, chemical accumulation, and heavy metal burden.
Supplement companies built genetic interpreters that analyzed 23andMe data to identify specific SNIPS and their associations with chronic illnesses. The field became fixated on detoxification, promoting the narrative that MTHFR defects, MTRR defects, COMT variants, and related genes indicated poor detoxification capacity. Companies tracking patients on personalized detox programs with specialized methylfolate, hydroxy B12, lysine, and taurine regimens found few individuals actually improving. The clinical model failed despite significant patient investment in these regimens.
MTHFR focus was replaced by other trends including MCAS, with Dr. Afron's work published in 2014, followed by renewed focus on Epstein-Barr virus, then connective tissue issues. HLA and MTHFR fit into similar categories regarding their overstated clinical significance.
HLA originated from Dr. Shoemaker's 2002 poster based on a small subject group suggesting certain HLA patterns indicated vulnerability to exposure, without deeper scientific investigation. The 24% population prevalence figure for HLA defects does not hold up under scrutiny, with some studies showing up to 90% prevalence in certain populations. If 24% were accurate, large randomized control trials would show 24% non-response rates, which has not been observed.
Three disease categories associated with HLA problems demonstrate the opposite of Shoemaker's assertion. Post-borreliosis and ABPA (allergic bronchopulmonary aspergillosis) show HLA presence increases likelihood of autoimmune processes rather than innate immune inflammation. The Shoemaker model suggests HLA prevents transition from innate to adaptive immunity, reducing T-cell and B-cell activation, while avoiding autoimmune condition concepts.
Modern science reveals molecular echoing and molecular scarring where cells retain memory of toxic load exposure. The integrated stress response of mitochondria can become stuck in the on position through specific gene sequences. Vulnerability and being stuck in disease states occur through mechanisms other than HLA.
Extracellular ATP cannot currently be measured in blood as a danger signal. GDF-15 and FGF-21 serve as stress or danger indicators emerging from mitochondrial research. These tests inform clinical care by indicating which CDR phase a patient may be experiencing, though individual cells can exist in different CDR stages simultaneously.
CDR1 represents the house on fire state triggered by biotoxins, chemical toxins, heavy metals, pathogens like Lyme or candida, dysbiosis, and gut abnormalities. CDR2 begins when the fire is extinguished, inflammation resolves, MMP9 and C4A normalize, visual contrast sensitivity improves, diet is corrected, microbiome is fixed, pathogens are addressed, and compounds are drained.
GENIE testing shows gene transcript changes indicating hypometabolism and proliferative physiology, also called aerobic glycolysis or the Warburg effect. Cells preferentially burn sugar rather than oxygen even when oxygen is present. This shift supports tissue rebuilding, as demonstrated by brain development being 30% dependent on aerobic glycolysis until adulthood. The body intentionally shifts to this state for repair purposes.
Brain and heart are the two organs most dependent on aerobic glycolysis for repair. The body's shift into Warburg effect is predictable when inflammation persists and tissue changes occur. TGF-beta 1 and VEGF function as growth factors indicating the body's repair potential rather than abnormal findings requiring suppression.
CDR2 requires healthy metabolism with adequate substrates and nutrients for tissue rebuilding, plus properly functioning mitochondria. Metabolism can be measured through cortisol, insulin, thyroid, nutrients, and reproductive hormones. Mitochondrial function measurement remains the biggest blind spot in current clinical practice.
The integrated stress response of mitochondria represents the first signaling pathway turning on CDR, beginning with OMA1 and ending with ATF4 upregulation. GDF-15 and FGF-21 are the primary measurable compounds resulting from this pathway activation. Both markers together indicate mitochondrial origin of stress, with GDF-15 affecting the brain centrally causing nausea and appetite suppression, while FGF-21 works peripherally through beta-KLOTHO protecting liver, pancreas, and distinct brain regions.
The integrated stress response pathway can remain permanently upregulated even after trigger removal, keeping mitochondria in a primed stress state with continued CDR signaling. GDF-15 and FGF-21 testing is available through Children's Hospital of Colorado, though logistically challenging, with Mayo Clinic being more restrictive.
Elevated GDF-15 and FGF-21 can create false positives across multiple markers including C4A, TGF-beta 1, and GENIE findings like MAP kinases and toxicant receptors. Patients may pursue unnecessary home remediation and repeated testing when the issue stems from unaddressed CDR rather than ongoing exposure.
Emotional trauma buried in the nervous system may impair progression beyond CDR2. Long-term illness can create trauma or pre-existing trauma can predispose to illness development. The SERS model inadequately addresses vagal nerve function, autonomic nervous system balance, and parasympathetic tone.
Emotional trauma must be addressed as part of the healing process. Ignoring it keeps patients in the cell danger response. For many people, addressing the psychological landscape releases them from CDR. No special peptide, nutrient, or hormone replaces the need to fully deal with psychological issues. An injured nervous system and injured emotional psyche must not be underestimated in this illness.
Neil Nathan advocates addressing emotional trauma upfront. A more nuanced approach suggests some patients need foundational work first: getting out of exposure, passing the visual contrast sensitivity test, reducing inflammation, and feeling better before addressing emotional issues. The decision to place emotional work in CDR2 or CDR3 depends on how significant the emotional landscape is for each patient.
The limbic system and nervous system may still perceive a threat even when it has diminished to a kitten. Recalibration is needed. Focusing on the limbic and vagal piece first is particularly important for sensitive patients who cannot tolerate treatment. One capsule of charcoal may cause a two-week setback. Addressing limbic and vagal function first may smooth responses and increase treatment tolerance.
CIRS involves ongoing activation of innate immunity without proper adaptive immune response. Key questions include how to calm innate immune overactivation while supporting adaptive immune response, and how to optimize communication between these systems. Vitamin D may help mitigate dysregulation on the adaptive side.
The first bridge between antigen presentation and adaptive immune response is T-cells and T-cell receptors. Section 12 of GENIE typically shows downregulation in T-cell receptor function. Practical assessment involves looking at specific T-helper cell panel: CD3 counts, CD4 counts, and natural killer counts. These indicate whether the adaptive immune system has been impaired or remains suppressed.
T-helper panel testing is not done upfront because if CDR1 and CDR2 are addressed correctly, the adaptive immune response tends to come back online naturally. The panel serves as a gating tool for CDR3 to assess whether everything necessary has been done. After moving through CDR1 and CDR2, metabolic optimization, and mitochondrial optimization, the check occurs at CDR3.
CDR3 evaluation includes inflammatory markers: MMP9, IL6, neutrophil-lymphocyte ratio, CRP, and visual contrast sensitivity test to assess ongoing inflammation and exposure. CDR2 markers include GDF-15, FGF-21, and T-helper panel. Reactivated viruses are also assessed because they may appear secondary to illness but often resolve when other treatments are addressed correctly.
Epstein-Barr, CMV, and HHV6 are DNA viruses intercalated into DNA that cannot be fully eliminated. Strengthening the immune system is the best approach to managing these viruses. When other treatments are addressed, viral markers such as Epstein-Barr early antigen tend to improve as the immune system comes back online.
CDR2 focuses on clinical immunometabolism. Mitochondrial markers are assessed when available. Metabolic markers may need to be rechecked. The goal is to ensure CDR2 is cemented with all building blocks in place, including metabolism and immune system function.
CDR3 represents safety signals. VIP and MSH are assessed along with heart rate variability, cortisol, and hormones. Chronobiology patterns and biological variation are evaluated because the body may sedate normal mechanisms under threat. Flattening of chronobiology signals indicates the HPA axis has been turned down due to excessive stress.
Most patients follow their heart rate variability from the beginning of treatment. Improvement is tracked over time. Persistent low HRV indicates need for focused CDR3 work. Biological regulators such as peptides (VIP, KPV) are used to improve this final phase.
Remapping determines whether residual CDR1 remains despite prior work, whether CDR2 markers have normalized, whether the immune system has come back online, and whether metabolism is balanced. Ideally GDF-15 and FGF-21 normalize, confirming CDR3 status. Final healing, repair, and full recovery occur at this stage.
Following the CDR model correctly addresses multiple issues regardless of inciting cause (COVID, emotional stress, Lyme, mold). The process removes exposure, balances metabolism, regulates immune system, fixes nutrient pools, and balances hormones.
Different cells and neighboring cells can be in different CDR stages simultaneously. Measurements represent averages of the predominant CDR stage across cells. No method exists to measure or treat each cell differently. The approach treats the whole person and assesses overall progression.
The visual contrast sensitivity test is tied to validated symptom scales and quality of life markers, which are the best research methods for tracking patient improvement. When patients progress through CDR stages with improving self-report and objective markers, the approach is confirmed as effective.
Five main sensor pathways trigger the cell danger response: TRP, prostaglandins, PTX3, CGRP, and the PACAP-VIP pathway. These pathways converge to the integrated stress response of mitochondria, which activates ATF4 and sends the signal to turn on CDR, resulting in extracellular ATP extrusion.
Each pathway detects different signals, but signals are often pleiotropic and activate multiple pathways simultaneously. Water-damaged buildings with mycotoxins, lipopolysaccharides, beta-glucans, MVOCs, and bacteria trigger all five pathways while suppressing PACAP and VIP. Chemical exposures, heavy metals, chronic stress, EMFs, radiation, and chronic infections all map to these sensor pathways.
TRP is concentrated in the respiratory system and likely activated by inhaled mycotoxins. Inhaled nasal VIP may be particularly beneficial for respiratory TRP activation. Chewable VIP bypasses TRP but may trigger pathways effectively. Some patients respond better to inhaled VIP while others respond better to chewable VIP. Both may be combined sequentially to target all five pathways.
GADD34 is the enzyme that removes the danger signal by dephosphorylating EIF2A, turning off the integrated stress response. Natural compounds supporting GADD34 include bioflavonoids (quercetin, bromelain), antioxidants, and newer anti-aging compounds like jinenine. GLP-1 agonists may support GADD34 through a global mechanism.
Microdosing GLP-1s may sedate mast cell activity and support GADD34. This approach is considered when CDR1 work has been completed, triggers removed, and exposure extinguished, yet the stress mitochondrial state persists.
Low-dose VIP given upfront to hypersensitive patients who cannot tolerate binders may work through GADD34 to offload the stress response, reducing reactivity and enabling initial treatments like binders.
The approach removes triggers, quiets alarms, and sends safety signals. CDR1 puts out the fire, CDR2 rebuilds, and CDR3 moves back in.
Average time in CDR1 is six months, primarily due to home remediation coordination, assessment, remediation work, and small particle cleaning. Other triggers (chemicals, metals, pathogens, microbiome issues) resolve faster unless true Lyme disease is present.
CDR2 involves assessing metabolism and mitochondrial function using Seahorse and citrate synthase testing. Targeted nutrient repletion, hormonal therapy, peptides, or other compounds restore mitochondrial function. This phase takes two to three months to establish the plan.
VIP treatment requires a minimum of six months, averaging six to twelve months. Additional supportive treatments (nutrients, peptides) may be needed. CDR3 also addresses residual emotional issues, heart rate variability training, vagal tone measurement, vagal nerve stimulators, and emotional trauma work. This phase adds another six to twelve months.
Full recovery typically requires at least two years. Most people feel significantly better relatively early in the process when the model is followed correctly. The approach rebuilds the entire person rather than offering quick fixes. Anyone promising quick recovery is selling snake oil. The molecular biology of Naviaux shows each step is specifically gated and takes time.
Patients who fully recover emphasize the spirit of persistence and not giving up. The process requires changing environment, mental health, and biology to reset the system and increase resiliency.
Recovery involves prioritizing self-care and recognizing that retaining health is a lifelong process. Returning to previous behaviors will not produce different results.
CDR1 treatment has three documented phases: Phase 1 is brain health and trigger removal (silencing the alarm), Phase 2 is pathogen reduction (clearing hidden infections), and Phase 3 is gastrointestinal health and antigenic load reduction (healing the gut and rebuilding nutrition).
Common inciting triggers include mold, COVID or spike proteins, Lyme co-infections, and endotoxins. These initiate the cell danger response. Persistence factors are separate issues that must be addressed but are not the original triggers. Traumatic brain injury is also mentioned as a potential factor.
Dr. Heyman addresses the challenge of differentiating between initiating events that activate the cell danger response and ongoing factors that maintain persistence. He notes that stressors like tick bites, heavy metals, chemicals, EMFs, viruses, and actinobacteria could function as either inciting or persisting factors depending on the individual case.
Dr. Heyman identifies two common patient stories: a gradual decline without clear starting point, making diagnosis difficult, and a distinct event marking the beginning of symptoms. He observes that patients frequently report a major stressful period—divorce, loss of a loved one, or emotional destabilization—occurring one to two years before noticeable illness. This suggests that emotional stress may serve as a primer that activates the innate immune system, creating vulnerability before environmental exposures become problematic.
Dr. Heyman shares his own experience: a tick bite initiated his illness, but he was already under significant stress from medical school, being older than classmates, and feeling disconnected from peers due to prior life experience as a practitioner. Despite the tick bite, it took nearly 10 years to feel truly sick, illustrating how multiple stressors compound over time.
Dr. Heyman believes the medical community tends to overread tick bites and Lyme disease, with too many false positives in testing. Having run a clinic in Virginia, ground zero for Lyme, he found the testing murky and unreliable, though he acknowledges Lyme is real and can be difficult to detect.
Metals and chemicals rarely trigger the cell danger response unless exposure is major. Dr. Heyman cites a patient exposed to chemically contaminated environments through work, noting that significant exposure reaches a threshold, but for average people these are background noise contributing to persistence rather than initiation. Food alone does not trigger illness but acts as a persister by creating internal damage.
Stress emerges as a major trigger, both as a primer and ongoing factor. Dr. Heyman notes that the constant effort required to maintain status quo in today's world predisposes people to flipping into the cell danger response.
Overtraining syndrome in high-level athletes provides a model for understanding chronic illness. Athletes who push too far develop inflammatory chemistry, hormonal abnormalities, and sickness syndrome with proinflammatory states. With rest and recovery, most recover, though endurance athletes may experience prolonged post-exertional malaise and abnormal aerobic glycolysis visible on cardiopulmonary testing.
Metals, chemicals, and reactivated viruses constitute background noise that can be addressed over time. Dr. Heyman uses phospholipids and drainage support to gradually remove these compounds while focusing on major triggers: environment, stress, and certain infections.
Phase one focuses on silencing the alarm by removing ongoing environmental chemical triggers, clearing biotoxins, supporting liver and bile drainage, and reducing neuroinflammation. This involves either removing external exposures or removing the patient from exposure.
Dr. Heyman emphasizes that air sampling alone is insufficient—what's needed is comprehensive testing including surface sampling, dust sampling, and VOC measurement. Small particle cleaning is important but insufficient without source removal. Fogging without source removal cannot resolve environmental triggers.
The fundamental mistake in environmental medicine is believing a healthy environment is sterile. Dr. Heyman advocates shifting from a sterile versus non-sterile model to one of immune tolerance. Research from Italian hospitals demonstrated that aerosolizing healthy bacteria to compete with pathogens reduced hospital-acquired infections more effectively than chemical cleaning alone. This suggests homes should maintain healthy microbial balance rather than attempting sterility.
True environmental healing requires two simultaneous processes: cleaning the home and building patient resiliency through offloading triggers, improving immune response, supporting detoxification, balancing mitochondria, and reducing stress mode. The goal is developing microbiome tolerance rather than achieving a sterile environment.
Beyond biotoxins, noxious chemicals from cleaning agents and household products represent a significant but underaddressed exposure source. Dr. Heyman recommends Branch Basics' free course "Toss the Toxins" to teach patients chemical removal from homes. Both chemical and microbial issues require equal attention.
EMFs represent the murkiest of the three major environmental categories, with unclear mitigation strategies, though likely contributing to overall burden.
Dr. Heyman describes himself as a "lumper" rather than splitter, preferring integrative approaches. He used clay, charcoal, and zeolite long before entering mold and Lyme medicine. Prescription bile acid sequestrants like Welchol and cholestyramine effectively bind inflammatory compounds and mycotoxins, helping patients pass visual contrast sensitivity testing. However, after passing the visual test and cleaning diet and home, he transitions to natural binders like charcoal, clay, and chlorella for residual mycotoxin removal.
Dr. Heyman moves from a Shoemaker model initially to a Neil Nathan approach for deeper detoxification, using lipids, bile support, and other agents to strip residual mycotoxin load. He acknowledges that patients continue carrying toxic burden even after passing visual contrast sensitivity testing.
For true heavy metal detoxification, prescription chelating agents are necessary. Dr. Heyman's preferred agent is DMSA, pulsed every Saturday and Sunday as a broad-spectrum chelator for mercury, lead, cadmium, and arsenic. Natural binders like charcoal provide broad gut detoxification but lack the specificity of prescription agents for mycotoxins.
After patients progress past visual contrast sensitivity testing, Dr. Heyman recommends his EnviroBind formula containing charcoal, bentonite, and other natural binders to continue pulling residual compounds while maintaining the longer, deeper detox approach.
Dr. Heyman's approach combines prescription binders initially for acute mycotoxin binding, then transitions to natural binders and drainage support for ongoing detoxification of chemicals, metals, and mycotoxins while addressing the broader cell danger response framework.
Keep BetterHealthGuy in your library
Save the videos and channels worth coming back to, and find them again in one place.
